Cost Effectiveness of Definitive Treatment Strategies for Autonomously Functioning Thyroid Nodules
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Kendyl M Carlisle und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Maryland Baltimore, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Thyroid Nodule, Markov Chains, Thyroidectomy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This study was supported by the ACS Faculty Research Fellowship [Yinin Hu], an NIH NCATS KL2TR003099, a T32 in Epidemiology of Aging-funded postdoctoral fellow…, NCI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Objective
Autonomously functioning thyroid nodules (AFTN) can be treated with antithyroid drugs, radioactive iodine (RAI), thyroid lobectomy or radiofrequency ablation (RFA). Although surgery is most definitive, some patients require lifelong hormone supplementation. RFA avoids this sequela, but its efficacy depends on nodule size. This study aims to compare the relative cost‐effectiveness of RAI, RFA and lobectomy for treatment of AFTNs. Study Design A Markov analysis model was created to simulate clinical outcomes, costs and utilities for three AFTN treatments: (1) thyroid lobectomy, (2) RAI, and (3) RFA. Patients This mathematical model was created using published literature and modeling.
Measurements
Transition probabilities, utilities and costs were extracted from published literature, Medicare, and RedBook. The willingness to pay threshold was set to $100,000 per quality‐adjusted life year. The model simulated 2‐year outcomes, reflecting RFA literature. Sensitivity analyses were conducted to account for uncertainty in model variables.
Results
In the base model, RAI dominated both lobectomy and RFA, with lower estimated cost ($2000 vs. $9452 and $10,087) and higher cumulative utility (1.89 vs. 1.82 and 1.78 quality‐adjusted life years). One‐way sensitivity analyses demonstrated that relative cost‐effectiveness between surgery and RFA was driven by the probability of euthyroidism after RFA and hypothyroidism after lobectomy. RFA becomes more cost‐effective than surgery if the rate of euthyroidism after ablation is higher than 69% (baseline 54%).
Conclusion
Based on published data, RAI is most cost‐effective in treating most AFTN. Surgery is more cost‐effective than RFA in most scenarios, but RFA may be more resource‐efficient for smaller nodules with a high likelihood of complete treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Maryland Baltimore, Baltimore, Maryland, USA.
- Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Surgery, Columbia University Medical Center, New York, New York, USA.
ORCID-Profile: Kendyl M Carlisle
Förderung
- This study was supported by the ACS Faculty Research Fellowship [Yinin Hu], an NIH NCATS KL2TR003099, a T32 in Epidemiology of Aging-funded postdoctoral fellow…
- NCI NIH HHS
- NIA NIH HHS
- NCATS NIH HHS
- American College of Surgeons
Zitieren
APA
Carlisle, K. M., Talaie, T., Khalid, S., Turner, D. J., Terhune, J. H., Kuo, J. H., Malek, R., & Hu, Y. (2025). Cost Effectiveness of Definitive Treatment Strategies for Autonomously Functioning Thyroid Nodules. Clinical Endocrinology. https://doi.org/10.1111/cen.15140
Vancouver
Carlisle KM, Talaie T, Khalid S, Turner DJ, Terhune JH, Kuo JH, et al. Cost Effectiveness of Definitive Treatment Strategies for Autonomously Functioning Thyroid Nodules. Clinical Endocrinology. 2025. doi:10.1111/cen.15140
BibTeX
@article{Carlisle2025,
author = {Carlisle, Kendyl M and Talaie, Tara and Khalid, Sualeha and Turner, Douglas J and Terhune, Julia H and Kuo, Jennifer H and Malek, Rana and Hu, Yinin},
title = {Cost Effectiveness of Definitive Treatment Strategies for Autonomously Functioning Thyroid Nodules},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15140}
}
EUVIMED